Back to Search Start Over

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

Authors :
Justin Kline
Ronald Levy
Joshua Brody
James N. Kochenderfer
Edmund K. Waller
Sundar Jagannath
Michael R. Bishop
David Siegel
David Avigan
Michael Boyiadzis
Jeffrey Miller
Rafat Abonour
Kenneth C. Anderson
Stephen M. Ansell
Lisa Barbarotta
Austin John Barrett
Koen Van Besien
P. Leif Bergsagel
Ivan Borrello
Jill Brufsky
Mitchell Cairo
Ajai Chari
Adam Cohen
Jorge Cortes
Stephen J. Forman
Jonathan W. Friedberg
Ephraim J. Fuchs
Steven D. Gore
Brad S. Kahl
Larry W. Kwak
Marcos de Lima
Mark R. Litzow
Anuj Mahindra
Nikhil C. Munshi
Robert Z. Orlowski
John M. Pagel
David L. Porter
Stephen J. Russell
Karl Schwartz
Margaret A. Shipp
Richard M. Stone
Martin S. Tallman
John M. Timmerman
Frits Van Rhee
Ann Welsh
Michael Werner
Peter H. Wiernik
Madhav V. Dhodapkar
Source :
Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)
Publication Year :
2016
Publisher :
BMJ Publishing Group, 2016.

Abstract

Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that are resulting in impressive clinical responses. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a hematologic malignancy Cancer Immunotherapy Guidelines panel consisting of physicians, nurses, patient advocates, and patients to develop consensus recommendations for the clinical application of immunotherapy for patients with multiple myeloma, lymphoma, and acute leukemia. These recommendations were developed following the previously established process based on the Institute of Medicine’s clinical practice guidelines. In doing so, a systematic literature search was performed for high-impact studies from 2004 to 2014 and was supplemented with further literature as identified by the panel. The consensus panel met in December of 2014 with the goal to generate consensus recommendations for the clinical use of immunotherapy in patients with hematologic malignancies. During this meeting, consensus panel voting along with discussion were used to rate and review the strength of the supporting evidence from the literature search. These consensus recommendations focus on issues related to patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. Overall, immunotherapy is rapidly emerging as an effective therapeutic strategy for the management of hematologic malignances. Evidence-based consensus recommendations for its clinical application are provided and will be updated as the field evolves.

Details

Language :
English
ISSN :
20511426
Volume :
4
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Journal for ImmunoTherapy of Cancer
Publication Type :
Academic Journal
Accession number :
edsdoj.058020890a704e00a7da52df34f259b6
Document Type :
article
Full Text :
https://doi.org/10.1186/s40425-016-0188-z